
CLAIMS

1. A compound according to formula (I):



(I)

wherein

A is -O- or -$CH_2$-;

n is 0 or 1;

$R^1$ is $C_{1-6}$alkyl or $C_{1-6}$haloalkyl;

$R^2$ is hydrogen, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl, $C_{2-6}$alkynyl, $C_{2-6}$alkenyl, $C_{1-6}$alkyl, halogen, cyano, $C_{1-6}$haloalkyl, NHC(O)$R^9$ or $OR^8$, wherein said $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl, $C_{2-6}$alkynyl, $C_{2-6}$alkenyl, $C_{1-6}$alkyl or $C_{1-6}$haloalkyl is optionally substituted with one to three $R^7$;

$R^5$ and $R^6$ are independently hydrogen, heterocyclyl, $C_{3-6}$cycloalkyl, aryl, heteroaryl or $C_{1-6}$alkyl, wherein said heterocyclyl, $C_{3-6}$cycloalkyl, aryl, heteroaryl or $C_{1-6}$alkyl is optionally substituted with one or two substituents independently selected from halogen, $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, cyano or $OR^8$;
or $R^5$ and $R^6$ together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents

independently selected from oxo, halogen, $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, cyano, or $OR^8$; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system;

$R^7$ is independently $C_{1-6}$alkyl, halogen, cyano, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl, $OC_{1-6}$haloalkyl, $C_{2-6}$alkynyl or $C_{2-6}$alkenyl, wherein said $C_{1-6}$alkyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl, $OC_{1-6}$haloalkyl, $C_{2-6}$alkynyl or $C_{2-6}$alkenyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl and $OC_{1-6}$haloalkyl;

$R^8$ is independently hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkynyl, $C_{1-6}$haloalkyl, aryl or heteroaryl, wherein said $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano and $C_{1-6}$alkyl;

$R^9$ is a heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, $OR^8$, $C_{1-6}$haloalkyl or $C_{1-6}$alkyl;

wherein said heteroaryl refers to a heteroaromatic heterocycle having 1 to 20 carbon atoms and one or more heteroatoms independently selected from sulfur, oxygen and nitrogen; and

wherein said heterocyclyl refers to a saturated, unsaturated or partially saturated, monocyclic, bicyclic or tricyclic ring containing 3 to 20 atoms of which 1, 2, 3, 4 or 5 ring atoms are independently chosen from nitrogen, sulphur and oxygen;

as a free base or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^1$ is $C_{1-3}$alkyl.

3. A compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein $R^1$ is methyl or ethyl.

4. A compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein $R^2$ is aryl, heteroaryl, $C_{2-6}$alkynyl, halogen, $NHC(O)R^9$ or $OR^8$, wherein said aryl, heteroaryl, or $C_{2-6}$alkynyl is optionally substituted with one to three $R^7$.

5. A compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein $R^5$ and $R^6$ are independently hydrogen or heterocyclyl wherein said heterocyclyl is optionally substituted with one or two substituents independently selected from $C_{1-6}$alkyl or $OR^8$.

6. A compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein $R^5$ and $R^6$ together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, $C_{1-6}$alkyl or $OR^8$; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system.

7. A compound according to any one of claims 1-4 or 6, or a pharmaceutically acceptable salt thereof, wherein $R^5$ and $R^6$ together with the carbon to which they are attached form a cyclohexyl ring, which is substituted with $OR^8$.

8. A compound according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is independently $C_{1-6}$alkyl, halogen, cyano, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl or $C_{2-6}$alkynyl, wherein said $C_{1-6}$alkyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl or $C_{2-6}$alkynyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl and $OC_{1-6}$haloalkyl.

9. A compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein $R^8$ is independently $C_{1-6}$alkyl, $C_{2-6}$alkynyl or $C_{1-6}$haloalkyl.

10. A compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein $R^9$ is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, $OR^8$, $C_{1-6}$haloalkyl or $C_{1-6}$alkyl.

11. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is -O- or $-CH_2-$;
n is 0 or 1;

$R^1$ is $C_{1-6}$alkyl;

$R^2$ is $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl, $C_{2-6}$alkynyl, halogen, $NHC(O)R^9$ or $OR^8$; wherein said $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl or $C_{2-6}$alkynyl is optionally substituted with one to three $R^7$;

$R^5$ and $R^6$ are independently hydrogen or heterocyclyl, wherein said heterocyclyl is optionally substituted with one or two substituents independently selected from halogen, $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, cyano or $OR^8$;
or $R^5$ and $R^6$ together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, $C_{1-6}$alkyl or $OR^8$; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system;

$R^7$ is independently $C_{1-6}$alkyl, halogen, cyano, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl or $C_{2-6}$alkynyl, wherein said $C_{1-6}$alkyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl or $C_{2-6}$alkynyl, is optionally substituted with 1-3 substituents independently selected from halogen, cyano, $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl and $OC_{1-6}$haloalkyl;

$R^8$ is independently $C_{1-6}$alkyl, $C_{2-6}$alkynyl or $C_{1-6}$haloalkyl, wherein said $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano or $C_{1-6}$alkyl; and

$R^9$ is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, $OR^8$, $C_{1-6}$haloalkyl or $C_{1-6}$alkyl;

12. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is -O- or $-CH_2-$;
n is 0 or 1;

$R^1$ is $C_{1-3}$alkyl;

$R^2$ is aryl, heteroaryl, $C_{2-6}$alkynyl, halogen, $NHC(O)R^9$ or $OR^8$, wherein said aryl, heteroaryl or $C_{2-6}$alkynyl is optionally substituted with one to three $R^7$;

$R^5$ and $R^6$ are independently hydrogen or heterocyclyl, wherein said heterocyclyl is optionally substituted with two substituents independently selected from $C_{1-6}$alkyl;

or $R^5$ and $R^6$ together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, $C_{1-6}$alkyl or $OR^8$; and ring B is optionally fused with an aryl or heteroaryl to form a bicyclic system;

$R^7$ is independently $C_{1-6}$alkyl, halogen, cyano, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl or $C_{2-6}$alkynyl, wherein said $C_{1-6}$alkyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl or $C_{2-6}$alkynyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, $OC_{1-6}$alkyl and $OC_{1-6}$haloalkyl;

$R^8$ is independently $C_{1-6}$alkyl, $C_{2-6}$alkynyl or $C_{1-6}$haloalkyl, wherein said $C_{1-6}$alkyl, $C_{1-6}$haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano or $C_{1-6}$alkyl; and

$R^9$ is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, $OR^8$, $C_{1-6}$haloalkyl or $C_{1-6}$alkyl;

13. A compound according to claim 1, selected from the group consisting of:

- 6-(3,5-Dichlorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(5-Chloropyridin-3-yl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(3,5-Difluorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(3,5-dimethylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,5-dimethoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,3-difluorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,5-dimethylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(5-fluoro-2-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-3-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-methoxy-5-methylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-5-methylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-5-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-chloro-pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-(trifluoromethyl)pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-but-2-ynoxy-pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-but-2-ynoxy-pyrazine-2-carboxamide;

- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-methyl-thiophene-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-3,5-dichloro-pyridine-2-carboxamide;
- 6'-bromo-4-(difluoromethoxy)-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[4-(prop-1-yn-1-yl)pyridin-2-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)benzene-1,3-dicarbonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-fluoropyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluorobenzonitrile;
- 6'-(3,3-dimethylbut-1-yn-1-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclopropylethynyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-bromopyrimidine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(trifluoromethyl)pyridine-2-carboxamide;

- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloro-3-methyl-1-benzofuran-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-3,5-dichloropyridine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloropyridine-2-carboxamide;
- 4-methoxy-5"-methyl-6'-(2-methylpropoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3,3,3-trifluoropropoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(3-fluoropropoxy)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5-methyl-2",3",5",6"-tetrahydro-3'*H*-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-(3-chlorophenyl)-5-methyl-2",3",5",6"-tetrahydro-3'H-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-(3-chloro-4-fluorophenyl)-5-methyl-2",3",5",6"-tetrahydro-3'H-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-bromo-4,4-difluoro-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-4,4-difluoro-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- N-(4"-amino-4,4-difluoro-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloropyridine-2-carboxamide;
- 5'-bromo-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 5'-(3-chlorophenyl)-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 6'-bromo-5-methyl-5",6"-dihydro-4"*H*-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;

- 6'-(3-chlorophenyl)-5-methyl-5",6"-dihydro-4"H-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;
- 6'-(3-chloro-4-fluorophenyl)-5-methyl-5",6"-dihydro-4"H-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;
- 6-bromo-5'-methyl-2-tetrahydropyran-3-yl-spiro[chromane-4,2'-imidazole]-4'-amine;
- 6-(3-chlorophenyl)-5'-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,3-dihydrospiro[chromene-4,2'-imidazol]-4'-amine;
- 6-bromo-2-(2,2-dimethyltetrahydropyran-4-yl)-5'-methyl-spiro[chromane-4,2'-imidazole]-4'-amine;
- 6-(3-chlorophenyl)-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5'-methyl-2,3-dihydrospiro[chromene-4,2'-imidazol]-4'-amine;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloro-3-methylpyridine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluoropyridine-2-carboxamide;
- 4-methoxy-5"-methyl-6'-[2-(prop-1-yn-1-yl)pyridin-4-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[3-(prop-1-yn-1-yl)phenyl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-bromopyridin-3-yl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4,4-difluoro-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5'-(5-chloropyridin-3-yl)-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-5'-[5-(prop-1-yn-1-yl)pyridin-3-yl]dispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 7'-bromo-5-methyl-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;
- 7'-(5-chloropyridin-3-yl)-5-methyl-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;

- 5-methyl-7'-(5-(prop-1-ynyl)pyridin-3-yl)-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;
- 6'-bromo-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-5"-methyl-3'H-dispiro[cyclobutane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclobutane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclopropylethynyl)-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(3, 3-dimethylbut-1-yn-1-yl)-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(5-chloro-6-methylpyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloro-2-methylpyridin-3-yl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[4-methyl-5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5"-ethyl-4-methoxy-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)pyridine-3-carbonitrile;
- 3-(4"-amino-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)benzonitrile;
- 6'-[5-(but-1-yn-1-yl)pyridin-3-yl]-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 4"-amino-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4-ol;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methylbenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-bromo-5"-methyl-3'H-dispiro[cyclopropane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-3'H-dispiro[cyclopropane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazole]-6'-carbonitrile;
- 4-methoxy-6'-[3-(methoxymethyl)phenyl]-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[3-fluoro-5-(methoxymethyl)phenyl]-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-{5-[(2,2,2-trifluoroethoxy)methyl]pyridin-3-yl}-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(5-methylpyridin-3-yl)-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(trifluoromethyl)benzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(difluoromethyl)benzonitrile;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-methoxybenzonitrile;
- 6'-(3,5-difluorophenyl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2-fluoro-3-methoxyphenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-

1',2"-imidazol]-4"-amine;

- 4-methoxy-5"-methyl-6'-phenyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methoxybenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-bromobenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-ethylbenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(methoxymethyl)benzonitrile;
- 6'-(2-fluoro-5-methoxyphenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2,5-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-3-chloro-2-fluorobenzonitrile;
- 6'-(2,3-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-4-fluorobenzonitrile;
- 6'-(2,4-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2,3-dichlorophenyl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methoxybenzonitrile;
- 4-(difluoromethoxy)-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'H-


dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 4-(difluoromethoxy)-6'-(3,5-difluorophenyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-methoxybenzonitrile;
- 4-methoxy-4,5"-dimethyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclobutylethynyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3-methylbut-1-yn-1-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-{5-[($^2H_3$)prop-1-yn-1-yl]pyridin-3-yl}-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-oxodispiro[cyclohexane-1,2'-[1H]indene-1'(3'H),2"-[2H]imidazol]-6'-yl)-5-fluorobenzonitrile;
- 4-methoxy-5"-methyl-6'-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[5-(difluoromethyl)pyridin-3-yl]-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3-methyl-1H-indol-5-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 5"-methyl-4-[($^2H_3$)methyloxy]-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[2-chloro-3-(prop-1-yn-1-yl)phenyl]-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-methyl-4-(trifluoromethyl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 6'-(cyclobutylmethoxy)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-(methoxymethyl)benzonitrile;
- 6'-bromo-4-(difluoromethyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-4-(difluoromethyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-4-ethoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-ethoxy-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-ethoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-4-ethoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-ethoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(difluoromethyl)benzonitrile; and
- 4-ethoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine,


or a pharmaceutically acceptable salt of any foregoing compound.

14. A compound according to claim 1, which is (1r,1'R,4R)-4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine:




or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1, which is 3-[(1r,1'R,4R)-4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl]-5-chlorobenzonitrile:



or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1, which is (1r,4r)-4-methoxy-5"-methyl-6'-(2-methyl-propoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine (isomer 1):


(isomer 1),

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in association with at least one pharmaceutically acceptable excipient, carrier or diluent.

18. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use as a medicament.

19. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing an Aβ-related pathology.

20. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

21. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing Alzheimer's disease.

22. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

23. The use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of an Aβ-related pathology.

24. The compound of claim 22, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's

Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

25. The use of claim 23, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

26. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of Alzheimer's Disease in a patient in need thereof.


27. Use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of Alzheimer's Disease in a patient in need thereof.

28. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, for use in the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

29. Use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor , in the manufacture of a medicament for the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

CLAIMS

1. A compound that is (1r,1'R,4R)-4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in association with at least one pharmaceutically acceptable excipient, carrier or diluent.

3. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, for use as a medicament.

4. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, for treating or preventing an A$\beta$-related pathology, wherein said A$\beta$-related pathology is Down's syndrome, a $\beta$-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, Alzheimer's Disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

5. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, for treating or preventing Alzheimer's disease.

6. The use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of an A$\beta$-related pathology,

wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, Alzheimer's Disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

7. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of Alzheimer's Disease in a patient in need thereof.

8. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, for use in the treatment or prevention of an Aβ-related pathology in a patient in need thereof, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, Alzheimer's Disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

9. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor , in the manufacture of a medicament for the treatment or prevention of an Aβ-related pathology in a patient in need thereof, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, Alzheimer's Disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.